Enhancement of the dissolution rate and gastrointestinal absorption of pranlukast as a model poorly water-soluble drug by grinding with gelatin

International Journal of Pharmaceutics

Volumn 347, Issue 1-2, 2008, Pages 71-78

  Chono, Sumio ^a   Takeda, Eri ^a   Seki, Toshinobu ^a   Morimoto, Kazuhiro ^a  

^a HOKKAIDO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

Dissolution rate; Gastrointestinal absorption; Gelatin; Grinding; Poorly water soluble drug; Pranlukast

Indexed keywords

GELATIN; PRANLUKAST;

ANIMAL EXPERIMENT; ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; GASTROINTESTINAL ABSORPTION; GRINDING; HUMAN; HUMAN CELL; NONHUMAN; PH MEASUREMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; X RAY DIFFRACTION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-ASTHMATIC AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CALORIMETRY, DIFFERENTIAL SCANNING; CHROMONES; DRUG STABILITY; ELECTRIC IMPEDANCE; GELATIN; HUMANS; HYDROGEN-ION CONCENTRATION; INTESTINAL ABSORPTION; MALE; POWDERS; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; X-RAY DIFFRACTION;

EID: 36549025974     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.06.037     Document Type: Article

References (28)

1. Cortesi R., Esposito E., Osti M., Squarzoni G., Menegatti E., Davis S.S., and Nastruzzi C. Dextran cross-linked gelatin microspheres as a drug delivery system. Eur. J. Pharm. Biopharm. 47 (1999) 153-160
2. Daumesnil R. How to fully exploit the market potential of poorly soluble actives? Case studies. Proceedings of the 27th Mini-Symposium & APSTJ Global Education Seminar East 3-05, September 2005. Tokyo, Japan (2005)
3. Fukunaka Y., Iwanaga K., Morimoto K., Kakemi M., and Tabata Y. Controlled release of plasmid DNA from cationized gelatin hydrogels based on hydrogel degradation. J. Control. Release 80 (2002) 333-343
4. Horter D., and Dressman J.B. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv. Drug Deliv. Rev. 46 (2001) 75-87
5. Imai T., Nishiyama T., Ueno M., and Otagiri M. Enhancement of the dissolution rates of poorly water-soluble drugs by water-soluble gelatin. Chem. Pharm. Bull. 37 (1989) 2251-2252
6. Imai T., Kimura S., Iijima T., Miyoshi T., Ueno M., and Otagiri M. Rapidly absorbed solid oral formulations of ibuprofen using water-soluble gelatin. J. Pharm. Pharmacol. 42 (1990) 615-619
7. Ishido M., Shibakawa K., Nakao Y., Sawada M., and Aishita H. Studies on the metabolic fate of leikotriene antagonist ONO-1078 (1): absorption, distribution and excretion after single administration to rats. Xenobio. Metabol. Dispos. 8 (1993) 2-26
8. Kallinteri P., and Antimisiaris S.G. Solubility of drugs in the presence of gelatin: effect of drug lipophilicity and degree of ionization. Int. J. Pharm. 221 (2001) 219-226
9. Kantaria S., Rees G.D., and Lawrence M.J. Gelatin-stabilised microemulsion-based organogels: rheology and application in iontophoretic transdermal drug delivery. J. Control. Release 60 (1999) 355-365
10. Kimura S., Nishiyama T., Imai T., and Otagiri M. Improved dissolution and absorption of drugs using low molecular gelatin. Acta Pharm. Nord. 2 (1990) 65-72
11. Lipinski C.R. Poor aqueous solubility-an industry-wide problem in ACME ascreening. Apsugel Symposium on Oral Delivery of Poorly Soluble Actives-From Drug Discovery to Marketed Products, June 2003. Tokyo, Japan (2003)
12. Morimoto K., Katsumata H., Yabuta T., Iwanaga K., Kakemi M., Tabata Y., and Ikada Y. Gelatin microspheres as a pulmonary delivery system: evaluation of salmon calcitonin absorption. J. Pharm. Pharmacol. 52 (2000) 611-617
13. Morimoto K., Katsumata H., Yabuta T., Iwanaga K., Kakemi M., Tabata Y., and Ikada Y. Evaluation of gelatin microspheres for nasal and intramuscular administrations of salmon calcitonin. Eur. J. Pharm. Sci. 13 (2001) 179-185
14. Morimoto K., Chono S., Kosai T., Seki T., and Tabata Y. Design of novel injectable cationic microspheres based on aminated gelatin for prolonged insulin action. J. Pharm. Pharmacol. 57 (2005) 839-844
15. Mura P., Faucci M.T., and Parrini P.L. Effects of grinding with microcrystalline cellulose and cyclodextrins on the ketoprofen physicochemical properties. Drug Dev. Ind. Pharm. 27 (2001) 119-128
16. Mura P., Cirri M., Faucci M.T., Gines-Dorado J.M., and Bettinetti G.P. Investigation of the effects of grinding and co-grinding on physicochemical properties of glisentide. J. Pharm. Biomed. Anal. 30 (2002) 227-237
17. Oguchi T., Sasaki N., Hara T., Tozuka Y., and Yamamoto K. Differentiated thermal crystallization from amorphous chenodeoxycholic acid between the ground specimens derived from the polymorphs. Int. J. Pharm. 253 (2003) 81-88
18. Parrott E.L. Thermal hardness coefficient of tablets. J. Pharm. Sci. 70 (1981) 328-329
19. Rasenack N., Hartenhauer H., and Muller B.W. Microcrystals for dissolution rate enhancement of poorly water-soluble drugs. Int. J. Pharm. 254 (2003) 137-145
20. Saito M., Ugajin T., Nozawa Y., Sadzuka Y., Miyagishima A., and Sonobe T. Preparation and dissolution characteristics of griseofulvin solid dispersions with saccharides. Int. J. Pharm. 249 (2002) 71-79
21. Seki T., Kanbayashi H., Nagao T., Chono S., Tomita M., Hayashi M., Tabata Y., and Morimoto K. Effect of aminated gelatin on the nasal absorption of insulin in rats. Biol. Pharm. Bull. 28 (2005) 510-514
22. Seki T., Kanbayashi H., Nagao T., Chono S., Tabata Y., and Morimoto K. Effect of cationized gelatins on the paracellular transport of drugs through caco-2 cell monolayers. J. Pharm. Sci. 95 (2006) 1393-1401
23. Surana R., Pyne A., and Suryanarayanan R. Effect of preparation method on physical properties of amorphous trehalose. Pharm. Res. 21 (2004) 1167-1176
24. Vippagunta S.R., Maul K.A., Tallavajhala S., and Grant D.J. Solid-state characterization of nifedipine solid dispersions. Int. J. Pharm. 236 (2002) 111-123
25. Wang J., Sakai S., Deguchi Y., Bi D., Tabata Y., and Morimoto K. Aminated gelatin as a nasal absorption enhancer for peptide drugs: evaluation of absorption enhancing effect and nasal mucosa perturbation in rats. J. Pharm. Pharmacol. 54 (2002) 181-188
26. Welz R., and Muller S. 5-(Benzylmercapto)-1H-tetrazole as activator for 2′-O-TBDMS phosphoramidite building blocks in RNA synthesis. Tetrahedron Lett. 43 (2002) 795-797
27. Wongmekiat A., Tozuka Y., Oguchi T., and Yamamoto K. Formation of fine drug particle by cogrinding with cyclodextrins. II. The influence of moisture condition during cogrinding process on fine particle formation. Int. J. Pharm. 265 (2003) 85-93
28. Yamada T., Saito N., Imai T., and Otagiri M. Effect of grinding with hydroxypropyl cellulose on the dissolution and particle size of a poorly water-soluble drug. Chem. Pharm. Bull. 47 (1999) 1311-1313